Within 10 years there will be 24 million new cancer sufferers - this is how to care for all them
More equitable access to treatments to greater diversity in clinical trials can help us tackle the global impact of cancer.
Susanne Schaffert Phd, President, Novartis Oncology.
Dr Susanne Schaffert has been President of Novartis Oncology since January 2019. She is a member of the Executive Committee of Novartis and currently sits on the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
For more than 20 years, Susanne has dedicated her career at Novartis to helping patients live longer, better lives. Before assuming her role as President of Novartis Oncology, Susanne served as Chairperson and President of Advanced Accelerator Applications (AAA) since its acquisition by Novartis in January 2018. Prior to this, Susanne was the Head of Region Europe at Novartis Oncology, where she was responsible for leading Novartis’ Oncology Business Unit in the European Region, marketing key products in lung, breast and renal cancer, as well as hematology and coordinating the entire Oncology operations for EU countries.
From 2010 to 2012, Susanne served as the Head of Investor Relations for Novartis Group, reporting to the Chief Financial Officer. Before this, she served as the Novartis Global Franchise Head for Immunology and Infectious Diseases.
Susanne first joined Novartis Germany in 1995, as a sales representative, and she has held a series of positions in Sales & Marketing with increasing responsibilities in both National and Global functions. Her roles have included Global Brand Director, Basel; Head of Marketing Oncology, Germany; Business Unit Head Oncology, Germany and Head of Northern & Central Europe for Novartis Oncology.
Susanne holds an M.Sc. in Chemistry and a Ph.D. with honors in Organic Chemistry from University of Erlangen (Germany).